Filing Flows › Foghorn Therapeutics (FHTX) › Q1 2025
Foghorn Therapeutics (FHTX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Foghorn Therapeutics (FHTX) reported revenue of $6.0M for the first quarter 2025 (Q1 2025), +18% from a year earlier and +108% from the quarter before. Operating margin was -385.0%, net loss $18.8M (316.4% of revenue).
Foghorn Therapeutics, Q1 2025: revenue $6.0M (+18% year over year), operating margin -385.0%, net loss $18.8M, operating cash flow −$24.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.0M | +108% | +18% |
| Operating profit | −$22.9M | — | — |
| Net earnings | −$18.8M | — | — |
| Operating cash flow | −$24.0M | — | — |
What changed
Revenue was $6.0M in Q1 2025, up 18% year over year and up 108% from the previous quarter.
Operating costs exceeded revenue by $22.9M, an operating margin of -385.0%. Total costs fell 13% while revenue rose 18%. The quarter ended with a net loss of $18.8M, narrower than the previous quarter's $19.5M loss. Non-operating items added $4.1M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$24.0M. Non-cash charges added back $827K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $28K exceeded it, leaving free cash flow of −$24.0M.
Questions
What was Foghorn Therapeutics' revenue in the first quarter 2025?
Foghorn Therapeutics (FHTX) reported revenue of $6.0M for the first quarter 2025 (Q1 2025), +18% from a year earlier and +108% from the quarter before.
Was Foghorn Therapeutics profitable in the first quarter 2025?
Operating loss was $22.9M (-385.0% of revenue) and net loss $18.8M.